The US Patent and Trademark Office (USPTO) has granted Patent No 7,654,955 to Entelos, entitled 'Apparatus and Methods for Assessing Metabolic Substrate Utilisation'. These methods are likely to strengthen the Entelos Metabolism PhysioLab platform and leverage insights about human physiology that, the company feel, can lead to improved diagnosis, clinical testing, and personalised treatment.

The company said that the newly patented method extends the ability of the Entelos Metabolism PhysioLab platform to explore, simulate, and predict differences in fuel utilisation between patients, a key predictor in responses to treatment. This method may also be used to improve the selection of patients for clinical trials of metabolic therapies and diagnostics.

Jeff Trimmer, CSO of Entelos, said: “We are pleased to add this new patent to cap our leadership position in metabolic disorders such as diabetes and obesity. Our biosimulation platforms and insightful ‘what if’ scenarios have already led to better decisions in R&D and this new diagnostic capability can stratify patients based on underlying differences in their disease state to optimize care.”